Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis
- 2018-01-01
- Pediatrics 141(1)
- V. Sung
- F. D'Amico
- M. Cabana
- Kim Chau
- G. Koren
- F. Savino
- H. Szajewska
- G. Deshpande
- C. Dupont
- F. Indrio
- S. Mentula
- Anna Partty
- D. Tancredi
- PubMed: 29279326
- DOI: 10.1542/peds.2017-1811
Abstract
Context: Lactobacillus reuteri DSM17938 has shown promise in managing colic, but conflicting study results have prevented a consensus on whether it is truly effective.
Objective: Through an individual participant data meta-analysis, we sought to definitively determine if L reuteri DSM17938 effectively reduces crying and/or fussing time in infants with colic and whether effects vary by feeding type.
Data sources: We searched online databases (PubMed, Medline, Embase, the Cumulative Index to Nursing and Allied Health Literature, the Database of Abstracts of Reviews of Effects, and Cochrane), e-abstracts, and clinical trial registries.
Study selection: These were double-blind randomized controlled trials (published by June 2017) of L reuteri DSM17398 versus a placebo, delivered orally to infants with colic, with outcomes of infant crying and/or fussing duration and treatment success at 21 days.
Data extraction: We collected individual participant raw data from included studies modeled simultaneously in multilevel generalized linear mixed-effects regression models.
Results: Four double-blind trials involving 345 infants with colic (174 probiotic and 171 placebo) were included. The probiotic group averaged less crying and/or fussing time than the placebo group at all time points (day 21 adjusted mean difference in change from baseline [minutes] -25.4 [95% confidence interval (CI): -47.3 to -3.5]). The probiotic group was almost twice as likely as the placebo group to experience treatment success at all time points (day 21 adjusted incidence ratio 1.7 [95% CI: 1.4 to 2.2]). Intervention effects were dramatic in breastfed infants (number needed to treat for day 21 success 2.6 [95% CI: 2.0 to 3.6]) but were insignificant in formula-fed infants.
Limitations: There were insufficient data to make conclusions for formula-fed infants with colic.
Conclusions: L reuteri DSM17938 is effective and can be recommended for breastfed infants with colic. Its role in formula-fed infants with colic needs further research.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus reuteri | Improved Treatment Success in Infants with Colic | Beneficial | Moderate |
Lactobacillus reuteri ATCC PTA 5289 | Effectiveness in Breastfed Infants | Beneficial | Large |
Lactobacillus reuteri ATCC PTA 5289 | Improved Treatment Success | Beneficial | Large |
Lactobacillus reuteri HA-188 | Overall Treatment Success | Beneficial | Moderate |
Lactobacillus reuteri HA-188 | Reduced Crying Time | Beneficial | Moderate |
Lactobacillus reuteri HA-188 | Successful Treatment in Breastfed Infants | Beneficial | Large |
Lactobacillus reuteri LRE02 | Improved Colic Symptoms | Beneficial | Large |
Lactobacillus reuteri LRE02 | Improved Treatment Success for Colic | Beneficial | Large |
Lactobacillus reuteri MAK02L14R | Improved Treatment Success | Beneficial | Large |
Lactobacillus reuteri NCIMB 30242 | Improved Treatment Success | Beneficial | Large |
Lactobacillus reuteri Osfortis | Improved Health in Breastfed Infants | Beneficial | Large |
Lactobacillus reuteri Osfortis | Increased Treatment Success for Infant Colic | Beneficial | Moderate |
Lactobacillus reuteri Osfortis | Reduced Efficacy of Formula Feeding in Infants | Neutral | Small |
Lactobacillus reuteri SD-5865 | Improved Health in Breastfed Infants | Beneficial | Large |
Lactobacillus reuteri SD-5865 | Improved Treatment Success | Beneficial | Large |
Lactobacillus reuteri UALg-05 | Increased Treatment Success for Infant Colic | Beneficial | Moderate |